NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
TRANSTHERA-TT420C2308
Phase III
OPEN TO ACCRUAL
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physicians Choice in Subjects with FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma